Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Indivior PLC Ordinary Shares (INDV)
Top performer.
Today’s top pick
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: INDV (5-star) is a STRONG-BUY. BUY since 5 days. Simulated Profits (10.02%). Updated daily EoD!
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $36.71
1 Year Target Price $36.71
| 5 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 128.26% | Avg. Invested days 38 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.00B USD | Price to earnings Ratio 32.65 | 1Y Target Price 36.71 |
Price to earnings Ratio 32.65 | 1Y Target Price 36.71 | ||
Volume (30-day avg) 7 | Beta 1.12 | 52 Weeks Range 7.62 - 32.34 | Updated Date 11/5/2025 |
52 Weeks Range 7.62 - 32.34 | Updated Date 11/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.98 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-10-23 | When - | Estimate 0.385 | Actual 0.72 |
Profitability
Profit Margin 6.27% | Operating Margin (TTM) 36.94% |
Management Effectiveness
Return on Assets (TTM) 13.15% | Return on Equity (TTM) 12.2% |
Valuation
Trailing PE 32.65 | Forward PE 12.3 | Enterprise Value 2758146013 | Price to Sales(TTM) 3.39 |
Enterprise Value 2758146013 | Price to Sales(TTM) 3.39 | ||
Enterprise Value to Revenue 2.35 | Enterprise Value to EBITDA 10.57 | Shares Outstanding 124853897 | Shares Floating 91219506 |
Shares Outstanding 124853897 | Shares Floating 91219506 | ||
Percent Insiders 3.87 | Percent Institutions 83.03 |
Upturn AI SWOT
Indivior PLC Ordinary Shares
Company Overview
History and Background
Indivior PLC (now Indivior Inc.) was formed as a spin-off from Reckitt Benckiser in 2014. It focuses on the treatment of addiction and related mental health disorders. Its history is rooted in developing and commercializing opioid dependence treatments, evolving to address broader addiction challenges.
Core Business Areas
- Opioid Dependence Treatment: Development and commercialization of treatments for opioid use disorder (OUD), primarily focusing on buprenorphine-based medications.
- Alcohol Dependence Treatment: Development and commercialization of treatments for alcohol use disorder (AUD).
- Pipeline Development: Research and development of new medications and formulations for addiction and related disorders.
Leadership and Structure
The company is led by a CEO and a management team. Organizational structure includes departments for R&D, commercial operations, finance, and legal.
Top Products and Market Share
Key Offerings
- Suboxone Film: A sublingual film containing buprenorphine and naloxone for opioid dependence treatment. It previously held a substantial market share but faces generic competition. Competitors include generic versions of buprenorphine/naloxone and other medication-assisted treatment (MAT) options. Revenue is declining due to generic entry and patent expiration, but still significant. Estimated market share decline from 60% in the past to a lower level due to competition.
- Sublocade: A once-monthly injectable buprenorphine for opioid dependence treatment. Sublocade is a strong competitor against Vivitrol and generic buprenorphine products. Revenue is growing, but faces competition from other MAT options. Market share around 20-25% for injectable buprenorphine therapies.
- Perseris: A once-monthly injectable risperidone for the treatment of schizophrenia in adults. Competitors include Invega Sustenna and Aristada. Market Share is niche.
Market Dynamics
Industry Overview
The addiction treatment market is driven by increasing awareness of substance use disorders and expanding access to treatment. Government initiatives and insurance coverage are key factors.
Positioning
Indivior is a key player in the opioid dependence treatment market, transitioning from reliance on Suboxone to new products like Sublocade. Competitive advantages include established brand recognition and expertise in addiction medicine.
Total Addressable Market (TAM)
The global addiction treatment market is estimated to be worth billions of dollars. Indivior is positioned to capture a significant share through its established treatments and expanding pipeline.
Upturn SWOT Analysis
Strengths
- Established brand recognition in addiction treatment
- Innovative injectable products like Sublocade
- Expertise in addiction medicine and regulatory affairs
- Strong pipeline of potential new treatments
Weaknesses
- Reliance on buprenorphine-based products
- Exposure to generic competition
- Past legal issues and settlements
- High R&D expenditure
Opportunities
- Expanding access to addiction treatment through telehealth
- Developing new treatments for other substance use disorders
- Partnering with healthcare providers and payers
- International expansion
Threats
- Increasing generic competition in the buprenorphine market
- Regulatory changes impacting reimbursement and access
- Competition from other pharmaceutical companies
- Negative public perception of addiction treatment
Competitors and Market Share
Key Competitors
- VTRS
- ALKS
Competitive Landscape
Indivior faces competition from generic buprenorphine products (Viatris - VTRS) and alternative MAT options like Vivitrol (Alkermes - ALKS). Indivioru2019s advantage lies in its innovative injectable formulations.
Growth Trajectory and Initiatives
Historical Growth: Past growth was driven by Suboxone. Current growth is being driven by Sublocade.
Future Projections: Analyst estimates project future growth driven by Sublocade and other pipeline products.
Recent Initiatives: Recent initiatives include focusing on Sublocade commercialization and developing new formulations.
Summary
Indivior is a pharmaceutical company specializing in addiction treatment, particularly opioid dependence. While facing generic competition for its legacy product Suboxone, it is strategically transitioning towards innovative injectable medications like Sublocade. The company's future hinges on the successful commercialization of Sublocade and other pipeline products. They must navigate regulatory challenges and competition while expanding access to treatment for substance use disorders.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company performance can change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Indivior PLC Ordinary Shares
Exchange NASDAQ | Headquaters North Chesterfield, VA, United States | ||
IPO Launch date 2014-12-29 | CEO & Director Mr. Joseph J. Ciaffoni | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 1030 | Website https://www.indivior.com |
Full time employees 1030 | Website https://www.indivior.com | ||
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). The company also offers OPVEE nasal spray for opioid overdose reversal. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. Indivior PLC was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.